Systematic (IUPAC) name | |
---|---|
10-(3-chlorophenyl)-3,4-dihydro-2H-pyrimido[1,2-a]indol-10-ol | |
Clinical data | |
Pregnancy cat. | ? |
Legal status | ? |
Routes | Oral |
Pharmacokinetic data | |
Metabolism | Renal[1] |
Half-life | ~32 hours[1] |
Excretion | Urine, Feces[1] |
Identifiers | |
CAS number | 37751-39-6 |
ATC code | ? |
PubChem | CID 37825 |
ChemSpider | 34683 |
UNII | Y3I9520J7P |
KEGG | D03486 |
Chemical data | |
Formula | C17H15ClN2O |
Mol. mass | 298.77 g/mol |
SMILES | eMolecules & PubChem |
Ciclazindol (WY-23,409) is an antidepressant and anorectic drug of the tetracyclic chemical class that was developed in the mid to late 1970s, but was never marketed.[2][3] It acts as a norepinephrine reuptake inhibitor, and to a lesser extent as a dopamine reuptake inhibitor.[2][4] Ciclazindol has no effects on the SERT, 5-HT receptors, mACh receptors, or α-adrenergic receptors, and has only weak affinity for the H1 receptor.[4][5][6] As suggested by its local anesthetic properties,[5] ciclazindol may also inhibit sodium channels. It is known to block potassium channels as well.[7][8]
|
|
|
|
|